Fig. 7
From: Increased TSPO alleviates neuropathic pain by preventing pyroptosis via the AMPK-PGC-1α pathway

Mitochondrial dysfunction was observed during pyroptosis induction in primary astrocytes. A Representative images of GFAP immunofluorescence staining to identify astrocytes, scale bar = 50 μm. B, C ELISA showing the levels of IL-1β and IL-18 in different groups, n = 6 per group. D Representative images of PI staining demonstrate the number of pyroptotic cells in the different groups, scale bar = 50 μm. E Western blot showing the expression levels of p-AMPK, PGC1, MFN2, and TFAM after ATP + LPS treatment. F Representative images of ROS staining indicate the level of ROS produced by astrocytes after ATP + LPS treatment, scale bar = 50 μm. G Representative images of MitoSOX staining show the level of mitochondrial ROS levels after ATP + LPS treatment, scale bar = 50 μm. H Representative images of JC-1 staining show a shift from aggregates (red) to monomers (green), indicating mitochondrial depolarization, scale bar = 50 μm. I Representative images of Mito-Tracker staining show mitochondrial morphology, scale bar = 20 μm. J Quantification of mitochondrial aspect ratio, n = 6 per group. K Western blot showing the expression levels of TSPO, NLRP3, Caspase-1, and GSDMD-N after ATP + LPS treatment. Data are represented as mean ± SEM, ***p < 0.001